DUK
45
3
APD
34
-5
KIM
48
-6
BXP
42
-5
QRVO
59
-22
AXP
71
-2
SYY
48
-2
GE
67
-3
CME
48
-2
K
38
-3
ALLE
41
-5
PGR
74
4
YUM
57
-9
PFE
33
10
MDLZ
65
-4
AON
19
2
VRTX
62
4
SEE
48
4
CB
47
3
HUM
36
2
DUK
45
3
APD
34
-5
KIM
48
-6
BXP
42
-5
QRVO
59
-22
AXP
71
-2
SYY
48
-2
GE
67
-3
CME
48
-2
K
38
-3
ALLE
41
-5
PGR
74
4
YUM
57
-9
PFE
33
10
MDLZ
65
-4
AON
19
2
VRTX
62
4
SEE
48
4
CB
47
3
HUM
36
2
Financhill
Back

Loncar Cancer Immunotherapy ETF Stock Predictions

Stock Market Legend Shares Biggest Prediction Ever:

Click Here to See
Sell
50

CNCR
Loncar Cancer Immunotherapy ETF

Last Price:
15.44
Seasonality Move:
1.87%

7 Day Trial

ALL ACCESS PASS

$ 7

DeFi Coin Triggers All "Buy" Signals And Could Break Out Soon

Discover our top DeFi pick for potentially massive gains now (before it's too late).

Loncar Cancer Immunotherapy ETF Stock Forecast

  • Over the next 52 weeks, Loncar Cancer Immunotherapy ETF has on average historically fallen by 3.2% based on the past 8 years of stock performance.
  • Loncar Cancer Immunotherapy ETF has fallen lower in 4 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is Loncar Cancer Immunotherapy ETF Stock Undervalued?
    The current Loncar Cancer Immunotherapy ETF [CNCR] share price is $15.44. The Score for CNCR is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Loncar Cancer Immunotherapy ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Loncar Cancer Immunotherapy ETF has on average historically fallen by 3.2% based on the past 8 years of stock performance.

Loncar Cancer Immunotherapy ETF Stock Rating

Sell
50
Loncar Cancer Immunotherapy ETF (CNCR) is a Sell

Is Loncar Cancer Immunotherapy ETF overpriced?

  • Loncar Cancer Immunotherapy ETF has fallen lower in 4 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

Loncar Cancer Immunotherapy ETF Stock Price History

Is CNCR stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CNCR is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
17.96
52-Week Low:
9.22

Prediction Charts

Market Cap:
0
Price in USD:
15.44
Volume:
82.84K
Beta:
1.13

Technical Analysis

SMA50:
15.92
SMA100:
14.88
SMA200:
13.07
52-Wk Change:
19.27%

Stock Predictions

  • Is Loncar Cancer Immunotherapy ETF stock public?
    Yes, Loncar Cancer Immunotherapy ETF is a publicly traded company.
  • What is the Loncar Cancer Immunotherapy ETF stock quote today?
    The Loncar Cancer Immunotherapy ETF stock price is 15.44 USD today.
  • How to buy Loncar Cancer Immunotherapy ETF stock online?
    You can buy Loncar Cancer Immunotherapy ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Apr-12 15.91 15.64 15.91 15.32
Apr-15 15.59 15.01 15.59 15.00
Apr-16 14.97 14.67 15.00 14.67
Apr-17 14.89 14.57 14.89 14.57
Apr-18 14.58 14.36 14.63 14.36
Apr-19 14.30 14.11 14.49 13.92
Apr-22 14.18 14.21 14.48 14.05
Apr-23 14.44 14.48 14.65 14.44
Apr-24 14.53 14.23 14.53 14.23
Apr-25 14.26 13.95 14.26 13.77
Apr-26 13.97 14.39 14.43 13.94
Apr-29 14.65 15.03 15.27 14.65
Apr-30 15.07 14.76 15.10 14.76
May-1 15.00 15.44 15.83 14.94

Loncar Cancer Immunotherapy ETF Earnings

Data Unavailable

Loncar Cancer Immunotherapy ETF Forecast Revenue Growth

Data Unavailable

* Loncar Cancer Immunotherapy ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.